MPN Watch

Dossier pubmed observational 15-sep-2026

Adaptations in pacritinib usage for myelofibrosis and thrombocytopenia since FDA approval.

Key claim: Since FDA approval, pacritinib use in myelofibrosis with thrombocytopenia has been adapted in clinical practice regarding how the drug is applied in this population.

Abstract

No abstract available.

Why this matters

Since FDA approval, pacritinib use in myelofibrosis with thrombocytopenia has been adapted in clinical practice regarding how the drug is applied in this population.

Source

Link

Briefing card

Adaptations in pacritinib usage for myelofibrosis and thrombocytopenia since FDA approval.
Stage: observational · pubmed · 15-sep-2026

Since FDA approval, pacritinib use in myelofibrosis with thrombocytopenia has been adapted in clinical practice regarding how the drug is applied in this population.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

🔎 Pulled in by auto-added search #67 (pubmed): "pacritinib"[Title/Abstract] AND (myelofibrosis[Title/Abstract] OR "myeloproliferative"[Title/Abstract] OR thrombocytopenia[Title/Abstract] OR IRAK1[Title/Abstract])

External: doi:10.1080/17474086.2026.2732995

Ask about this finding

Replies are grounded in the abstract and metadata above. The model will quote directly when possible and say so if a question isn't covered.

Subscribe: calendar of upcoming dates · deadlines feed · all new records · Help

build build 612 · 69ce4cf-dirty · 2026-11-11